

Apostolia Maria Tsimberidou

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8480145/apostolia-maria-tsimberidou-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

233
papers

10,536
citations

54
h-index

95
g-index

247
ext. papers

12,193
ext. citations

5.4
avg, IF

6.09
L-index

#	Paper	IF	Citations
233	AKT inhibition in the central nervous system induces signaling defects resulting in psychiatric symptomatology.. <i>Cell and Bioscience</i> , 2022 , 12, 56	9.8	1
232	Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors. <i>Cancer Medicine</i> , 2021 ,	4.8	4
231	Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. <i>British Journal of Cancer</i> , 2021 , 124, 1533-1539	8.7	6
230	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. <i>Npj Precision Oncology</i> , 2021 , 5, 21	9.8	2
229	Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. <i>Npj Precision Oncology</i> , 2021 , 5, 33	9.8	2
228	Overview of Ocular Side Effects of Selinexor. <i>Oncologist</i> , 2021 , 26, 619-623	5.7	2
227	Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	6
226	T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 102	22.4	13
225	Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. <i>Cancer</i> , 2021 , 127, 391-402	6.4	1
224	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 1247-1255	12.9	1
223	Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 1758835921100153	5.4	1
222	Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. <i>Oncologist</i> , 2021 , 26, 558-e1098	9.7	7
221	Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 127	22.4	5
220	Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory 2020 , 8,		5
219	Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020 , 21, 477-481	4.9	2
218	Phase I study of imalumab (BAX69), a fully human recombinant antioxidantized macrophage migration inhibitory factor antibody in advanced solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1836-1848	3.8	12
217	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. <i>Scientific Reports</i> , 2020 , 10, 3080	4.9	3

216	Phase 2 study of pembrolizumab in patients with advanced rare cancers 2020 , 8,		45
215	Review of precision cancer medicine: Evolution of the treatment paradigm. <i>Cancer Treatment Reviews</i> , 2020 , 86, 102019	14.4	86
214	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. <i>Experimental Hematology and Oncology</i> , 2020 , 9, 7	7.8	8
213	Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. <i>Oncotarget</i> , 2020 , 11, 1-14	3.3	0
212	Circulating tumor DNA analysis in the era of precision oncology. <i>Oncotarget</i> , 2020 , 11, 188-211	3.3	24
211	Transcriptomics and solid tumors: The next frontier in precision cancer medicine. <i>Seminars in Cancer Biology</i> , 2020 ,	12.7	11
210	Innovative trial design in precision oncology. <i>Seminars in Cancer Biology</i> , 2020 ,	12.7	3
209	Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. <i>Journal of Clinical Oncology</i> , 2019 , 37, 72-80	2.2	12
208	A nonparametric Bayesian basket trial design. <i>Biometrical Journal</i> , 2019 , 61, 1160-1174	1.5	3
207	Targeting () Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	7
206	Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 145	22.4	17
205	Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. <i>Cancers</i> , 2019 , 11,	6.6	8
204	Basket Trials and the MD Anderson Precision Medicine Clinical Trials Platform. <i>Cancer Journal (Sudbury, Mass)</i> , 2019 , 25, 282-286	2.2	8
203	Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine. <i>Cancer Journal (Sudbury, Mass)</i> , 2019 , 25, 296-299	2.2	2
202	Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 530-539	3.8	7
201	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. <i>Cancer</i> , 2019 , 125, 463-472	6.4	7
200	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2018 , 142, 1242-1253	5	72
199	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. <i>Lung Cancer</i> , 2018 , 120, 137-141	5.9	22

198	Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 1595-1601	6.1	18
197	Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 155-162	5.9	19
196	Authors' Reply. <i>Journal of Molecular Diagnostics</i> , 2018 , 20, 125-126	5.1	0
195	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2018 , 24, 181-188	12.9	89
194	Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. <i>Investigational New Drugs</i> , 2018 , 36, 416-423	4.3	13
193	Overview of precision oncology trials: challenges and opportunities. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 797-804	3.8	27
192	Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. <i>Oncotarget</i> , 2018 , 9, 28842-28848	3.3	3
191	Outcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancer. <i>Oncotarget</i> , 2018 , 9, 33258-33270	3.3	4
190	Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. <i>Oncotarget</i> , 2018 , 9, 33232-33243	3.3	15
189	Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 671-676	6.1	23
188	Complete Response to a Fibroblast Growth Factor Receptor Inhibitor in a Patient With Head and Neck Squamous Cell Carcinoma Harboring Amplifications. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	7
187	Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With -Mutated Malignancies. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	4
186	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1631-1641	2.2	448
185	Prolonged Partial Response to Bevacizumab and Valproic Acid in a Patient With Glioblastoma. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	2
184	Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement 2018 , 6, 108		11
183	A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 877-885	3.5	4
182	Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy. <i>Journal of Immunotherapy</i> , 2018 , 41, 336-339	5	5
181	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2017 , 23, 3657-3666	12.9	44

180	Cardiotoxicity of Anticancer Therapies 2017 , 15-42		3
179	Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine. <i>Current Problems in Cancer</i> , 2017 , 41, 176-181	2.3	15
178	Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. <i>Journal of Molecular Diagnostics</i> , 2017 , 19, 4-23	5.1	744
177	Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	67
176	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , 2017 , 2,	9.9	19
175	Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. <i>Clinical Cancer Research</i> , 2017 , 23, 4155-4162	12.9	3
174	Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 1463-1470	5.4	5
173	Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. <i>Oncology</i> , 2017 , 92, 14-20	3.6	3
172	Outcomes of patients ≥5 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. <i>International Journal of Cancer</i> , 2017 , 140, 208-215	7.5	7
171	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. <i>Clinical Cancer Research</i> , 2017 , 23, 1388-1396	12.9	199
170	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. <i>Oncotarget</i> , 2017 , 8, 33796-33806	3.3	3
169	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. <i>Oncotarget</i> , 2017 , 8, 87163-87173	3.3	
168	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2475-2485	6.1	49
167	Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. <i>Cancer</i> , 2016 , 122, 3401-3409	6.4	40
166	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. <i>Cancer Discovery</i> , 2016 , 6, 1352-1365	24.4	150
165	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1397-404	6.1	61
164	Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	60
163	Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e187-93	3.3	1

162	Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 575-81	3-5	5
161	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. <i>Oncotarget</i> , 2016 , 7, 67521-67531	3-3	36
160	Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. <i>Oncotarget</i> , 2016 , 7, 23227-38	3-3	19
159	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. <i>Oncotarget</i> , 2016 , 7, 35132-43	3-3	9
158	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. <i>Scientific Reports</i> , 2016 , 6, 35448	4-9	9
157	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. <i>Cancer Medicine</i> , 2016 , 5, 3437-3444	4-8	12
156	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. <i>Cancer Research</i> , 2016 , 76, 3690-701	10-1	154
155	Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 1097-102	3-5	3
154	Gene and cell therapy for pancreatic cancer. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 505-16	5-4	14
153	Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015 , 33, 215-24	4-3	6
152	A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. <i>Investigational New Drugs</i> , 2015 , 33, 177-86	4-3	20
151	Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 869-74	3-5	19
150	Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2015 , 33, 621-31	4-3	45
149	Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. <i>BMC Cancer</i> , 2015 , 15, 61	4-8	22
148	Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. <i>Clinical Epigenetics</i> , 2015 , 7, 29	7-7	11
147	A decision support framework for genomically informed investigational cancer therapy. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9-7	135
146	Targeted therapy in cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 1113-32	3-5	89
145	Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. <i>Investigational New Drugs</i> , 2015 , 33, 911-20	4-3	7

144 Combining Targeted Therapies **2015**, 14-26

143 Left ventricular ejection fraction in advanced cancer patients: a valuable prognostic tool?. *Future Oncology*, **2015**, 11, 1999-2002 3.6 1

142 Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. *Oncotarget*, **2015**, 6, 12809-21 3.3 77

141 Precision medicine: lessons learned from the SHIVA trial. *Lancet Oncology, The*, **2015**, 16, e579-80 21.7 45

140 Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. *BMC Cancer*, **2015**, 15, 713 4.8 33

139 Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. *Oncotarget*, **2015**, 6, 28453-62 3.3 8

138 BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. *Oncotarget*, **2015**, 6, 26886-94 3.3 38

137 Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. *Clinical Cancer Research*, **2014**, 20, 4827-36 12.9 150

136 Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. *Cancer*, **2014**, 120, 2164-73 6.4 25

135 MABp1, a first-in-class true human antibody targeting interleukin-1 β in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. *Lancet Oncology, The*, **2014**, 15, 656-66 21.7 141

134 A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, 395-400.e1 2 5

133 Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2014**, 12, 194-203 7.3 3

132 Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. *Oncotarget*, **2014**, 5, 3012-22 3.3 67

131 Precision cancer medicine: the future is now, only better. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2014**, 61-9 7.1 30

130 Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies. *Expert Opinion on Drug Metabolism and Toxicology*, **2014**, 10, 483-94 5.5 31

129 Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. *Molecular Cancer Therapeutics*, **2014**, 13, 3175-84 6.1 26

128 Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. *Clinical Cancer Research*, **2014**, 20, 6336-45 12.9 61

127 Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. *Clinical Cancer Research*, **2014**, 20, 5956-63 12.9 9

126	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. <i>Cell Reports</i> , 2014 , 6, 377-87	10.6	186
125	Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. <i>Investigational New Drugs</i> , 2014 , 32, 279-86	4.3	13
124	FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. <i>PLoS ONE</i> , 2014 , 9, e89388	3.7	42
123	MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. <i>Oncoscience</i> , 2014 , 1, 5-13	0.8	23
122	Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience. <i>Oncoscience</i> , 2014 , 1, 522-530	0.8	6
121	Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. <i>Oncoscience</i> , 2014 , 1, 540-9	0.8	20
120	Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. <i>Oncotarget</i> , 2014 , 5, 3029-38	3.3	36
119	Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. <i>Oncotarget</i> , 2014 , 5, 1846-55	3.3	27
118	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. <i>Oncotarget</i> , 2014 , 5, 2349-54	3.3	50
117	Characteristics and survival of patients with advanced cancer and p53 mutations. <i>Oncotarget</i> , 2014 , 5, 3871-9	3.3	10
116	Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. <i>Oncotarget</i> , 2014 , 5, 8937-46	3.3	6
115	Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. <i>Current Pharmaceutical Biotechnology</i> , 2014 , 15, 475-85	2.6	47
114	A pilot study of temsirolimus and body composition. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2013 , 4, 259-65	10.3	20
113	Anti-vascular endothelial growth factor therapy in the era of personalized medicine. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 1-12	3.5	16
112	Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 389-97	3.5	11
111	Antibody-independent isolation of circulating tumor cells by continuous-flow dielectrophoresis. <i>Biomicrofluidics</i> , 2013 , 7, 11807	3.2	165
110	Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 1265-71	3.5	3
109	Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. <i>Investigational New Drugs</i> , 2013 , 31, 1505-13	4.3	22

108	PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. <i>Cancer Research</i> , 2013 , 73, 276-84	10.1	221
107	Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013 , 13, 568-74	2	55
106	Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 118-25	7.1	18
105	A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 71, 955-63	3.5	13
104	Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. <i>Journal of Clinical Oncology</i> , 2013 , 31, e137-40	2.2	27
103	Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. <i>Clinical Cancer Research</i> , 2013 , 19, 4824-31	12.9	15
102	Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2857-63	6.1	35
101	Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2167-75	6.1	27
100	Strategies to Overcome Clinical, Regulatory, and Financial Challenges in the Implementation of Personalized Medicine. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 33, 118-125	7.1	13
99	Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. <i>Oncotarget</i> , 2013 , 4, 890-8	3.3	33
98	Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. <i>Oncotarget</i> , 2013 , 4, 772-84	3.3	15
97	Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. <i>Oncotarget</i> , 2013 , 4, 118-27	3.3	31
96	Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. <i>Oncotarget</i> , 2013 , 4, 156-65	3.3	29
95	P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. <i>Oncotarget</i> , 2013 , 4, 705-14	3.3	87
94	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2013 , 211-223		1
93	Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. <i>Hepato-Gastroenterology</i> , 2013 , 60, 1611-23		9
92	Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. <i>Cancer</i> , 2012 , 118, 1422-8	6.4	65
91	Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 297-303	3.8	6

90	Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. <i>Nutrition and Cancer</i> , 2012 , 64, 206-17	2.8	27
89	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. <i>Journal of Clinical Oncology</i> , 2012 , 30, 777-82	2.2	355
88	Lenalidomide in solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 1393-406	3.5	25
87	Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. <i>Clinical Cancer Research</i> , 2012 , 18, 2922-9	12.9	62
86	Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. <i>Clinical Cancer Research</i> , 2012 , 18, 6373-83	12.9	391
85	PIK3CA mutations in advanced cancers: characteristics and outcomes. <i>Oncotarget</i> , 2012 , 3, 1566-75	3.3	71
84	Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. <i>Hepato-Gastroenterology</i> , 2012 , 59, 960-4		1
83	PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. <i>PLoS ONE</i> , 2011 , 6, e22769	3.7	153
82	Common cardiovascular medications in cancer therapeutics. <i>Pharmacology & Therapeutics</i> , 2011 , 130, 177-90	13.9	49
81	PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 558-65	6.1	281
80	Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 247-53	3.5	18
79	Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1507-16	3.5	5
78	Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. <i>Cancer</i> , 2011 , 117, 77-85	6.4	6
77	Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. <i>Oncologist</i> , 2011 , 16, 327-35	5.7	8
76	Cardiovascular toxicity profiles of vascular-disrupting agents. <i>Oncologist</i> , 2011 , 16, 1120-30	5.7	66
75	Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 997-1005	5.6	84
74	Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. <i>Clinical Cancer Research</i> , 2011 , 17, 4110-8	12.9	21
73	Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 209-17	6.1	5

72	Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. <i>Oncologist</i> , 2011 , 16, 1292-8	5.7	53
71	Managing cardiac risk factors in oncology clinical trials. <i>Texas Heart Institute Journal</i> , 2011 , 38, 266-7	0.8	4
70	Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?. <i>Oncologist</i> , 2010 , 15, 130-41	5.7	96
69	Salirasib in the treatment of pancreatic cancer. <i>Future Oncology</i> , 2010 , 6, 885-91	3.6	36
68	Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 3410-9	6.1	35
67	Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1188-99	1.9	11
66	Farnesyltransferase inhibitors: where are we now?. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1569-80	5.9	33
65	Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. <i>Virology Journal</i> , 2010 , 7, 256	6.1	8
64	Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. <i>Clinical Breast Cancer</i> , 2010 , 10, 46-51	3	8
63	Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 235-41	3.5	33
62	Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 1087-93	3.5	16
61	Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2010 , 116, 880-7	6.4	21
60	A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. <i>Cancer</i> , 2010 , 116, 4086-94	6.4	22
59	Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 904-10	2.2	166
58	A phase I clinical trial of darinaparsin in patients with refractory solid tumors. <i>Clinical Cancer Research</i> , 2009 , 15, 4769-76	12.9	38
57	Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 4423-32	5.6	31
56	Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience. <i>American Journal of Hematology</i> , 2009 , 84, 408-13	7.1	11
55	Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2009 , 115, 373-80	6.4	88

54	Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. <i>Cancer</i> , 2009 , 115, 1091-9	6.4	62
53	Treatment of fludarabine-refractory chronic lymphocytic leukemia. <i>Cancer</i> , 2009 , 115, 2824-36	6.4	51
52	Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6243-50	2.2	69
51	Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience. <i>Journal of Pediatric Hematology/Oncology</i> , 2009 , 31, 803-11	1.2	42
50	Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2008 , 26, 196-203	2.2	124
49	The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. <i>Clinical Cancer Research</i> , 2008 , 14, 721-30	12.9	35
48	Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. <i>Cancer</i> , 2008 , 113, 1370-8	6.4	144
47	The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. <i>Cancer</i> , 2008 , 113, 1605-13	6.4	81
46	Relevance of clinical trials in acute myeloid leukaemia. <i>Hematological Oncology</i> , 2008 , 26, 182-3	1.3	6
45	Richter's transformation in chronic lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , 2007 , 2, 265-71	4.4	22
44	Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4648-56	2.2	70
43	Treatment of older patients with acute myeloid leukemia. <i>Aging Health</i> , 2007 , 3, 663-673		1
42	The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1931-9	1.9	85
41	Richter's transformation in chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2006 , 33, 250-6	5.5	59
40	Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. <i>Cancer</i> , 2006 , 107, 125-35	6.4	88
39	Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. <i>Cancer</i> , 2006 , 107, 1294-302	6.4	110
38	Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. <i>Journal of Clinical Oncology</i> , 2006 , 24, 1582-9	2.2	175
37	Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2343-51	2.2	208

36	Myeloid Sarcoma Involving the Gynecologic Tract. <i>American Journal of Clinical Pathology</i> , 2006 , 125, 783-790	1.9	57
35	Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1062-8	1.9	47
34	Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. <i>Leukemia and Lymphoma</i> , 2006 , 47, 827-36	1.9	31
33	Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2282-89	1.9	15
32	Induction mortality risk in adult acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1199-200	1.9	3
31	The role of gemtuzumab ozogamicin in acute leukaemia therapy. <i>British Journal of Haematology</i> , 2006 , 132, 398-409	4.5	51
30	Combination of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Richter's Syndrome and Fludarabine-Refractory Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2006 , 108, 2825-2825	2.2	1
29	Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 1267-73	8.9	125
28	Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. <i>Blood</i> , 2005 , 105, 1366-7	2.2	27
27	Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2005 , 29, 649-52	2.7	17
26	Richter syndrome: biology, incidence, and therapeutic strategies. <i>Cancer</i> , 2005 , 103, 216-28	6.4	222
25	Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. <i>Cancer</i> , 2005 , 104, 345-53	6.4	19
24	Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. <i>Cancer</i> , 2004 , 100, 342-9	6.4	66
23	Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. <i>Cancer</i> , 2004 , 100, 574-80	6.4	22
22	Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. <i>Cancer</i> , 2004 , 100, 2195-2006	6.4	35
21	Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2004 , 100, 2583-91	6.4	38
20	Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. <i>Leukemia Research</i> , 2004 , 28, 657-60	2.7	9
19	Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. <i>Leukemia Research</i> , 2004 , 28, 991-4	2.7	27

18	Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. <i>Journal of the American Academy of Dermatology</i> , 2004 , 51, 200-4	4.5	23
17	Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. <i>Cancer Chemotherapy and Pharmacology</i> , 2003 , 52, 229-34	3.5	9
16	Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2003 , 52, 449-52	3.5	29
15	Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or chronic lymphocytic leukemia. <i>Cancer</i> , 2003 , 97, 1711-18	6.4	94
14	Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. <i>Cancer</i> , 2003 , 97, 1721-31	6.4	35
13	Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. <i>Leukemia Research</i> , 2003 , 27, 375-80	2.7	53
12	Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1719-25	1.9	15
11	Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone. <i>Seminars in Oncology</i> , 2002 , 29, 48-55	5.5	13
10	Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 237-42	3.5	21
9	Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2002 , 50, 497-500	3.5	59
8	Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. <i>Leukemia Research</i> , 2002 , 26, 143-54	2.7	30
7	Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies. <i>Expert Review of Anticancer Therapy</i> , 2002 , 2, 437-48	3.5	56
6	TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies. <i>Expert Review of Anticancer Therapy</i> , 2002 , 2, 277-86	3.5	26
5	Essential thrombocythemia (ET): moving from palliation to cure. <i>Hematology</i> , 2002 , 7, 315-23	2.2	4
4	Quantitative real-time polymerase chain reaction for detection of circulating cells with t(14;18) in volunteer blood donors and patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1589-98	1.9	11
3	Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. <i>Leukemia and Lymphoma</i> , 2002 , 43, 767-72	1.9	52
2	Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. <i>Blood</i> , 2002 , 100, 4351-7	2.2	54
1	Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. <i>Leukemia and Lymphoma</i> , 2001 , 41, 535-44	1.9	11

